Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

I understood about every other word of that ("most folks have no idea what a null hypothesis is or what a p-value really says"...that's ME!).

The company itself has asserted on many occasions that a given trial "met its primary endpoint" or "met its secondary endpoint" after completing its own analysis. Many have referred to those trials as successful and asserted that IPIX has yet to fail one...presumably by that same "met its endpoint" measure.

Now we see the phrase appearing in a press release reporting a financing agreement (as a term of that agreement...ignoring for the moment the singular versus plural issue), yet:
The term "allows a company to claim it met endpoints as broadly as possible."

That's the point. Will Aspire share the Company's claim, should they make one, given that it can be made "as broadly as possible"? As you describe it it's hardly a defined standard.

As long as ONE participant achieves a 75% reduction from baseline in PASI score (PASI75) at Week 12 there will be SOME Proportion of participants that did so and hence the described endpoint will TECHNICALLY be met.
Is that what the parties had in mind when they agreed? Or did they reach some separate unstated understanding about what a null hypothesis is or what a p-value really says?